Vanda Pharmaceuticals (VNDA) Long-Term Investments (2011 - 2019)
Vanda Pharmaceuticals recorded quarterly Long-Term Investments of $61.8 million in Q3 2019, up 393.94% quarter-over-quarter from $12.5 million in Q2 2019.
Vanda Pharmaceuticals' Long-Term Investments history runs 2 years deep, the most recent figure standing at $61.8 million for Q3 2019.
- In Q3 2019, Long-Term Investments changed N/A year-over-year to $61.8 million; the TTM figure through Sep 2019 stood at $61.8 million (changed N/A YoY), while the FY2011 annual figure was $19.0 million, changed N/A from the prior year.
- Long-Term Investments came in at $61.8 million for Q3 2019 at Vanda Pharmaceuticals, up from $12.5 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $61.8 million in Q3 2019 to a low of $12.5 million in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 61.83 Mn |
| Jun 30, 2019 | 12.52 Mn |
| Dec 31, 2011 | 19.01 Mn |
| Sep 30, 2011 | 19.01 Mn |